Resources for a rapid response to COVID-19

The QIAstat-Dx Respiratory SARS-CoV-2 Panel

The 2019-2020 respiratory season has brought a new and unexpected challenge with SARS-CoV-2. To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates 21 respiratory targets, including SARS-CoV-2, from nasopharyngeal swabs (NPS) eluted in universal transport media (UTM).

Every diagnostic solution makes an impact

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is one Emergency Use Authorization solution available for the COVID-19 outbreak. To see a complete list of in vitro diagnostic products authorized for EUA, visit the FDA resource page.

See the complete list

Product details for the QIAstat-Dx Respiratory SARS-CoV-2 Panel

The QIAstat-Dx Respiratory SARS-CoV-2 Panel detects 21 viral and bacterial targets that are commonly responsible for upper respiratory infections, including the SARS-CoV-2 virus. Download the flyer below and visit the product page to view the technical resources.

Download the flyer

Product details


Learn more about the QIAstat-Dx Analyzer

The QIAstat-Dx Analyzer and cartridges are designed as a closed system that contains on board all necessary reagents, enabling hands-off sample preparation.

Download the brochure

SARS-CoV-2 verification controls

Each laboratory is responsible for defining its verification procedure and ensuring they meet state and federal guidelines. Guidelines for laboratory verification of performance of the QIAstat-Dx Respiratory SARS-CoV-2 Panel are available on our product page.

Our sample protocol was developed using the NATtrol™ Respiratory Verification Panel and the NATtrol SARS-CoV-2 (E/ORF1ab) recombinant available from ZeptoMetrix Corporation.

Download the flyer

Go to Zeptometrix

QIAGEN is committed to helping you fight COVID-19

QIAGEN supports several testing protocols by providing test components, mid- to high-throughput automation solutions, and a multiplex syndromic detection solution. We also support scientists seeking to better understand the SARS-CoV-2 virus with research tools, including sequencing components and tools for data analysis and interpretation. We will continue to work tirelessly on novel approaches.

Visit to learn more about how QIAGEN solutions can be used in the fight against COVID-19.

  • Real-time data on COVID-19 from Johns Hopkins University

    This tracker from the Johns Hopkins Center for Systems Science and Engineering pulls data from five sources and is updated in near real-time.

    Go to the global dashboard

How can we support your work?

Reach a specialist
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use under Emergency Use Authorization Only. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel has not been FDA cleared or approved;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized by FDA under an EUA for use by authorized laboratories;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Social Sharing